204 related articles for article (PubMed ID: 34648874)
21. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
[No Abstract] [Full Text] [Related]
22. Developmental Therapeutics in Myeloproliferative Neoplasms.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S43-S52. PubMed ID: 28760302
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).
Chen X; Williams WV; Sandor V; Yeleswaram S
J Clin Pharmacol; 2013 Jul; 53(7):721-30. PubMed ID: 23677817
[TBL] [Abstract][Full Text] [Related]
25. Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.
Zeitler K; Jariwala R; Alrabaa S; Sriaroon C
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34725058
[TBL] [Abstract][Full Text] [Related]
26. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
27. Achievements and future outlook for JAK inhibitors in polycythaemia vera.
Cakmak I; Harrison C
Expert Opin Pharmacother; 2023; 24(13):1491-1496. PubMed ID: 37343285
[TBL] [Abstract][Full Text] [Related]
28. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E; Gerds AT; Hobbs GS; Winton EF; Goel S; Wadleigh M; Tremblay D; Moshier E; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):697-703.e1. PubMed ID: 32624445
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.
Bai J; Ai L; Zhang L; Yang FC; Zhou Y; Xue Y
Am J Hematol; 2015 Dec; 90(12):1116-21. PubMed ID: 26370613
[TBL] [Abstract][Full Text] [Related]
30. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
32. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
33. Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Rastrelli M; Ferrazzi B; Tropea S; Costa A; Finotto S; Marino D; Campana L; Del Fiore P; Rossi CR; Alaibac M
In Vivo; 2019; 33(5):1667-1669. PubMed ID: 31471421
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
Chang L; Duan MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
[TBL] [Abstract][Full Text] [Related]
35. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
36. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
[TBL] [Abstract][Full Text] [Related]
37. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
[TBL] [Abstract][Full Text] [Related]
38. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
[TBL] [Abstract][Full Text] [Related]
39. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
[TBL] [Abstract][Full Text] [Related]
40. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Rampotas A; Carter-Brzezinski L; Somervaille TCP; Forryan J; Panitsas F; Harrison C; Witherall R; Innes AJ; Wallis L; Butt NM; Psaila B; Mead AJ; Carter M; Godfrey AL; Laing H; Garg M; Francis S; Ewing J; Teh CH; Cowen HB; Dyer P; McConville C; Wadelin F; Sahra A; McGregor A; Kulakov E; McLornan DP; Lambert J
Blood; 2024 Jan; 143(2):178-182. PubMed ID: 37963262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
